Intermittent Courses of Corticosteroids Also Present a Risk forPneumocystisPneumonia in Non-HIV Patients
Open Access
- 1 January 2016
- journal article
- research article
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2016, 1-7
Abstract
Introduction.Pneumocystispneumonia (PCP) is rising in the non-HIV population and associates with higher morbidity and mortality. The aggressive immunosuppressive regimens, as well as the lack of stablished guidelines for chemoprophylaxis, are likely contributors to this increased incidence. Herein, we have explored the underlying conditions, immunosuppressive therapies, and clinical outcomes of PCP in HIV-negative patients.Methods. Retrospective analysis of PCP in HIV-negative patients at Mayo Clinic from 2006–2010. The underlying condition, immunosuppressive therapies, coinfection, and clinical course were determined. PCP diagnosis required symptoms of pneumonia and identification of the organisms by visualization or by a real-time polymerase chain reaction.Results. A total of 128 cases of PCP were identified during the study period. Hematological malignancies were the predisposing condition for 50% of the patients. While 87% had received corticosteroids or other immunosuppressive therapies for >4 weeks prior to the diagnosis, only 7 were receiving PCP prophylaxis. Up to 43% of patients were not on daily steroids. Sixty-seven patients needed Intensive Care Unit (ICU) and 53 received mechanical ventilation. The mortality for those patients requiring ICU was 40%.Conclusions. PCP diagnosis in the HIV-negative population requires a high level of suspicion even if patients are not receiving daily corticosteroids. Mortality remains high despite adequate treatment.Keywords
Funding Information
- National Institutes of Health (HL112849, HL62150)
- National Institutes of Health (HL112849, HL62150)
- Annenberg Foundation (HL112849, HL62150)
- Hospital Universitario Virgen del Rocío, Seville (HL112849, HL62150)
This publication has 27 references indexed in Scilit:
- Pneumocystis Pneumonia in Patients Treated With RituximabChest, 2013
- IncreasingPneumocystisPneumonia, England, UK, 2000–2010Emerging Infectious Diseases, 2013
- Outcome of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction in patients without human immunodeficiency virus infectionRespirology, 2012
- Pneumocystis jirovecii testing by real-time polymerase chain reaction and direct examination among immunocompetent and immunosuppressed patient groups and correlation to disease specificityDiagnostic Microbiology and Infectious Disease, 2011
- Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murinaJournal of Experimental Medicine, 2010
- Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infectionRespirology, 2009
- B Cells Are Required for Generation of Protective Effector and Memory CD4 Cells in Response to Pneumocystis Lung InfectionThe Journal of Immunology, 2006
- Acute Respiratory Failure Due to Pneumocystis Pneumonia in Patients Without Human Immunodeficiency Virus InfectionChest, 2005
- Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresBritish Journal of Haematology, 2002
- Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without AIDSAmerican Review of Respiratory Disease, 1989